Share on LinkedInShare on LinkedIn

ARTICLE · 05 JANUARY 2018

Canadian Patent Law: 2017 Year In Review

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

2017 was a busy year in Canadian patent law. The contentious Promise Doctrine was rejected by the Supreme Court of Canada in AstraZeneca v Apotex, the largest monetary judgment ...

CanadaIntellectual Property

2017 was a busy year in Canadian patent law. The contentious Promise Doctrine was rejected by the Supreme Court of Canada in AstraZeneca v Apotex, the largest monetary judgment for patent infringement in Canadian history was awarded in The Dow Chemical Company v Nova Chemical, the Patented Medicines (Notice of Compliance) Regulations and the Patent Rules were significantly amended, and Bill C-30 introduced an ability to seek patent term restoration through a "Certificate of Supplementary Protection" in certain circumstances.  

This article summarizes these and other noteworthy decisions and developments in Canadian patent law from 2017.

NOTABLE CASES AND DECISIONS

Promise Doctrine Abolished – AstraZeneca v Apotex

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from